Alibaba Health Information Technology (241) H2 2026 earnings summary

Executive summary

• Revenue grew 12.0% year-over-year to RMB34,255.1 million, driven by pharmaceutical direct sales and digital services.

• Net profit increased 35.2% year-over-year to RMB1,936.3 million; adjusted net profit rose 19.3% to RMB2,326.2 million.

• Taobao and Tmall Healthcare Platform saw rising annual active users and merchant participation.

• Launched "Hydrion," a large medical AI model, expanding smart healthcare infrastructure.

Financial highlights

• Gross profit reached RMB8,210.1 million, up 10.5% year-over-year; gross margin was 24.0%.

• Fulfillment, selling, and marketing expenses increased, but as a percentage of revenue, both declined, reflecting improved efficiency.

• Basic EPS was RMB12.02 cents, up from RMB8.91 cents; diluted EPS was RMB11.95 cents.

• Cash and cash equivalents rose to RMB5,434.1 million from RMB2,218.3 million.

• Final dividend of RMB5.95 cents and special dividend of RMB13.52 cents per share proposed.

Outlook and guidance

• Plans to deepen AI integration and expand the closed-loop healthcare ecosystem.

• Focus on enhancing accessibility, efficiency, and new "AI + Healthcare" models.